Health Care·Pharmaceuticals·$4.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $3.09 | N/A | +184.79% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $3.09 | N/A | +184.79% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed satisfaction with the strong EPS results, highlighting ongoing efforts in partnerships and development. However, they did not provide specific guidance for future quarters.
We are pleased with our EPS performance this quarter.
Our focus remains on strategic partnerships and product development.
Ligand Pharmaceuticals reported a strong earnings per share, significantly exceeding expectations, which led to a notable increase in stock price. The positive EPS surprise suggests effective cost management or strong product performance. However, the lack of revenue data and guidance leaves some uncertainty about future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SBA COMMUNICATIONS C Class A REIT
Nov 3, 2025